Both intraductal and infiltrating ductal carcinoma are seen here.
同时看到导管内癌与浸润性导管癌。
This is evidence for their origin from an underlying ductal carcinoma.
此为他们起源于下方的导管癌的证据。
Methods The breast sonograms in 20 cases with ductal carcinoma in situ were analysed and compared with pathology.
方法对20例经病理确诊患者的声像图资料，结合病理进行综合分析。
At high magnification, the infiltrating ductal carcinoma of breast has pleomorphic cells infiltrating through the stroma.
高倍视野下，浸润性导管癌多形性癌细胞侵入基质。
Conclusions Squamoid eccrine ductal carcinoma is an exceedingly rare low-grade malignant tumor and can recur after excision but do not metastasize.
结论鳞样小汗腺导管癌是一种非常罕见的低度恶性肿瘤，局部切除后可复发，未见转移报道。
However, this ductal carcinoma is not confined to just the duct, but infiltrates outward into the surrounding stroma as an infiltrating ductal carcinoma.
然而，该导管内癌不仅限于导管，还向外浸润至周围间质而成了浸润性导管癌。
Here is a side by side comparison of the gross characteristics of a classic infiltrating ductal carcinoma on the left and a benign fibroadenoma on the right.
左边典型的浸润性导管癌与右边良性纤维腺瘤的肉眼特征的近距离比较。
Conclusions Acinar cell carcinoma is a high-grade tumor and different from pancreatic ductal carcinoma and endocrine tumors in the morphology and immunophenotype.
结论胰腺腺泡细胞癌属于高度恶性肿瘤，在细胞学形态和免疫表型方面均与胰腺导管细胞肿瘤以及胰腺内分泌肿瘤不同。
There was also significant difference between ductal carcinoma in situ (or with early infiltration) and invasive ductal carcinoma (P<0.05), and the former was weaker.
导管内癌（或伴早浸）与浸润性导管癌相比，表达水平低，差异有显著性意义（P<0.05）。
Purpose to explore the clinicopathologic characteristics, immunohistochemistry, diagnosis and differential diagnosis of squamoid eccrine ductal carcinoma of the scalp.
目的探讨头皮鳞样小汗腺导管癌的临床病理和免疫表型特征及诊断与鉴别诊断。
Background the high incidence of ductal carcinoma in situ (DCIS) and variations in its treatment motivate inquiry into the comparative effectiveness of treatment options.
导管原位癌(DCIS)的高发病率和治疗多样化促使人们探究各种治疗的比较效应。
After resection of pancreatic ductal carcinoma, 541 patients were randomized to one of four treatment groups: chemoradiotherapy, chemotherapy, both treatments, or observation only.
在胰导管癌切除术后，541名患者被随机分为4个治疗组：化放疗组、化疗组、化放疗与化疗联合应用组和单纯观察组。
In this trial, women aged at least 45 years with invasive ductal breast carcinoma undergoing breast-conserving surgery were enrolled.
在这个试验中，入选标准为年龄大于45岁经历保乳手术的浸润性导管癌的患者。
In this trial, women aged at least 45 years with invasive ductal breast carcinoma undergoing breast-conserving surgery were enrolled.
在这个试验中，入选标准为年龄大于45岁经历保乳手术的浸润性导管癌的患者。
应用推荐